In 2024, the Genomics market in the Asia Pacific region displayed prominent growth, shaped primarily by extensive investment, regulatory changes, technology uptake, and robust demand from diverse sectors. Significant impetus was found in government regulation and public investment, such as China's initiatives promoting genetic research and India’s increased funding for genomics-based biomedical research. Also, escalating disease cases called for more superior diagnostic processes which in turn enhanced genomic need at large across healthcare practices in these parts of Asia as well as Australia including Japan. The market also revealed faster adoption of new-gen sequencing among institutes of research located in Chinese and universities that were known to operate from Australia. In India, other ASEAN countries, merger and partnerships have gained popularity amongst local companies and their globally located counterparts.
The emergence of personalized medicines was also a reason that helped genome sequencing become more commonplace in healthcare sectors all across these countries with government support. However, one aspect, that marked 2024 was the faster technology adoption in the non-healthcare sectors in countries such as Japan and Korea and also, within agriculture and animal sectors of these nations. The precision offered by genomic tools saw increased utilization in crop improvement and livestock health, providing a broader perspective of the market in 2024. Combined, these drivers and trends constituted a dynamic and advancing Genomics market across the Asia Pacific.
